Bifogade filer
PDF
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Large Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Stockholm, Sweden, June 26, 2025- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that BioArctic's founder, Professor Lars Lannfelt, will receive the 2025 Hartwig Piepenbrock-DZNE Prize for his pioneering contributions to the understanding of Alzheimer's disease and to the development of the drug lecanemab. The prize is presented jointly by German Center for Neurodegenerative Diseases (DZNE) and the Piepenbrock Group. The award ceremony will take place in Bonn in November this year.
"I'm proud to have been awarded the 2025 Hartwig Piepenbrock-DZNE Prize. Being able to give hope and contribute to the treatment of patients affected by Alzheimer's disease is what has driven me throughout my research life," said Professor Lars Lannfelt. "It is inspiring to see how research in this field now has begun to take quantum leaps with the development of treatments such as lecanemab which demonstrated benefits to patients in the global Phase 3 Clarity AD trial using gold standard endpoints. Coupled with the introduction of modern diagnostic methods, I am convinced that we are facing a paradigm shift where, in time, we will be able to offer not just a slowdown in the progression of the disease but eventually be able to halt the disease process."
Professor Lars Lannfelt founded BioArctic together with Pär Gellerfors in 2003 to develop an antibody treatment based on Lannfelt's groundbreaking discoveries of the role of amyloid-beta protein in Alzheimer's disease. These discoveries are the basis for lecanemab, an antibody treatment developed in collaboration with the Japanese company Eisai. By binding to specific forms of amyloid-beta, which causes Alzheimer's disease, lecanemab helps to clear them from the brain, thereby altering the course of the disease.
Since 2011, the Hartwig Piepenbrock-DZNE Prize has been awarded every two years for outstanding research on neurodegenerative disorders. The prize is sponsored by the Piepenbrock Group and is awarded in remembrance of its former Chief Executive Officer and Chairman Hartwig Piepenbrock, who passed away after suffering from dementia. Prize winners are selected by an international committee, coordinated by DZNE. On this occasion, the prize will be awarded for the eighth time.
---
The information was released for public disclosure, through the agency of the contact persons below, on June 26, 2025, at 10.15 a.m. CET.
For further information, please contact:
Oskar Bosson, VP Communications and IR
E-mail: oskar.bosson@bioarctic.se
Phone: +46 70 410 71 80
About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company is the originator of Leqembi® (lecanemab) - the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with Eisai. BioArctic has a broad research portfolio within Alzheimer's disease, Parkinson's disease, ALS and enzyme deficiency diseases. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which improves the transport of drugs into the brain. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For more information, please visit www.bioarctic.com.